.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,763,269

« Back to Dashboard

Details for Patent: 7,763,269

Title:Therapeutic foam
Abstract: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimising the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.
Inventor(s): Wright; David Dakin Iorwerth (Buckinghamshire, GB), Harman; Anthony David (Oxfordshire, GB), Robinson; Nikki (Uxbridge, GB), Hodges; Garry (Middlesex, GB), Kadar; Adil (Middlesex, GB), Moggridge; Geoffrey D. (Cambridge, GB), Van Liew; Hugh (Barnstable, MA)
Assignee: BTG International Ltd. (London, GB)
Filing Date:Nov 17, 2004
Application Number:10/522,528
Claims:1. A method of making a foam comprising: providing two syringes connected by a connector, wherein syringe one is charged with a liquid phase and syringe two is charged with a gas phase, syringe one is charged with the liquid phase and the gas phase, or both syringes are charged with the liquid phase and the gas phase; and transferring the liquid phase and the gas phase repeatedly between the syringes to form a foam, wherein the liquid phase comprises at least one sclerosing agent and the gas phase consists essentially of gaseous nitrogen present in an amount ranging from 0.01% to 0.8% by volume and a physiologically acceptable gas mixture comprising 10% to 90% vol/vol carbon dioxide with the remaining gas oxygen.

2. The method of claim 1, wherein the liquid phase and gas phase passing between the syringes is caused to pass through a mesh comprising apertures with a maximum dimension ranging from 1 to 200 micron.

3. The method of claim 2, wherein the maximum dimension ranges from 2 to 50 micron.

4. The method of claim 2, wherein the maximum dimension ranges from 3 to 20 micron.

5. The method of claim 1, wherein the gas phase is at least 70% by volume oxygen.

6. A method of making a foam comprising: (a) providing a syringe comprising a barrel, a first plunger and a second plunger, the second plunger having an apertured plunger head which is adapted to be movable within the barrel independently of the first plunger, the syringe being charged with a liquid phase and a gas phase; and (b) oscillating the second plunger to form a foam; wherein the liquid phase comprises at least one sclerosing agent and the gas phase consists essentially of gaseous nitrogen present in an amount ranging from 0.01% to 0.8% by volume and a physiologically acceptable gas mixture comprising 10% to 90% vol/vol carbon dioxide with the remaining gas oxygen.

7. The method of claim 6, wherein the apertures in the second plunger have a maximum dimension ranging from 1 to 200 micron.

8. The method of claim 6, wherein the apertures in the second plunger have a maximum dimension ranging from 2 to 50 micron.

9. The method of claim 6, wherein the apertures in the second plunger have a maximum dimension ranging from 3 to 20 micron.

10. The method of claim 6, wherein the gas phase is at least 70% by volume oxygen.

11. A sterile pack comprising: (a) a syringe charged with at least one liquid sclerosing agent and a gas mixture consisting essentially of gaseous nitrogen present in an amount ranging from 0.01% to 0.8% by volume and a physiologically acceptable gas mixture comprising 10% to 90% vol/vol carbon dioxide with the remaining gas oxygen; (b) a gas atmosphere inside the pack having substantially the same composition as the said gas mixture in the syringe.

12. The sterile pack of claim 11, wherein the gaseous nitrogen is present in an amount ranging from 0.01% to 0.7% by volume.

13. The sterile pack of claim 11, wherein the gaseous nitrogen is present in an amount ranging from 0.01% to 0.6% by volume.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc